{
  "paper_id": "PMC10807317",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10807317/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "FIGURE 1.",
      "caption": "Graphical simplification of cell cycle phases, checkpoints and regulatory mechanisms in breast cancer.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de3f/10807317/96d28dc73a20/CTM2-14-e1544-g001.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de3f/10807317/96d28dc73a20/CTM2-14-e1544-g001.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de3f/10807317/96d28dc73a20/CTM2-14-e1544-g001.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de3f/10807317/96d28dc73a20/CTM2-14-e1544-g001.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "ctm21544-fig-0001",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de3f/10807317/96d28dc73a20/CTM2-14-e1544-g001.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10807317/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de3f/10807317/96d28dc73a20/CTM2-14-e1544-g001.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "FIGURE 3.",
      "caption": "Rationale and challenges for the potential development of cell cycle inhibitors in combination with other therapies in breast cancer. ADC, antibody–drug conjugate; HRD, homologous recombination deficiency; ICI, immune checkpoint inhibitor; ILD, interstitial lung disease; LFT, liver function tests; TME, tumour microenvironment.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de3f/10807317/fde19ec52977/CTM2-14-e1544-g004.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de3f/10807317/fde19ec52977/CTM2-14-e1544-g004.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de3f/10807317/fde19ec52977/CTM2-14-e1544-g004.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de3f/10807317/fde19ec52977/CTM2-14-e1544-g004.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "ctm21544-fig-0003",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de3f/10807317/fde19ec52977/CTM2-14-e1544-g004.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10807317/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de3f/10807317/fde19ec52977/CTM2-14-e1544-g004.jpg"
    }
  },
  "claims": [
    {
      "sentence": "At least four cell cycle checkpoints may be deregulated in breast cancer (BC) cells: the restriction point (G0/G1), the G1 checkpoint (G1/S), the G2 checkpoint (G2/M) and the mitosis‐associated spindle assembly checkpoint (SAC) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "From a mechanistic standpoint, genomic alterations associated with resistance may be divided into two categories: resistance through the disruption of the cell cycle machinery (including alterations in RB1, CCNE1, CDK6, CDK4, p16, CDK2, CDK7, CCND1 or INK) and resistance through compensatory upstream signalling (alterations in PI3K, PTEN, FGFR1/2, FAT1/HIPPO, ERBB2 or RAS signalling) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "59\n A number of pan‐CDK inhibitors (CDKi) have been studied over the last two decades with generally limited anti‐tumour activity and considerable toxicity (Figure 2 and Table 1).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "67\n, \n68\n, \n69\n\n\nFIGURE 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "70\n, \n71\n, \n72\n While the cyclin E‐CDK2 complex participates in the G1/S phase transition through RB1 phosphorylation, CDK7 exerts a wider role in cell cycle progress by acting as a CDK‐activating kinase (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "S PHASE\nEntry into S phase is essentially controlled by the CDK2/cyclinA complex, where CDK2 is activated by CDK4/6‐dependent E2F upregulation and by CDK7, and inhibited by DNA damage‐mediated cdc25A and WEE1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In humans, centriole initiation requires PLK4 serine/threonine kinase activity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "98\n, \n102\n, \n103\n\n,\n\n104\n\n\nSeveral small‐molecule PLK4 inhibitors have been developed with varying selectivity (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "DDR‐related kinases such as ATM and CHK2, and ATR and CHK1, prevent the G2/M transition by activating serine‐threonine kinases WEE1 and PKMYT1, which maintain inhibitory phosphorylation of CDK1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "71\n, \n118\n, \n127\n\n\nFour WEE1i, adavosertib, Debio 0123, IMP7068 and ZN‐c3, have entered clinical trials (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "155\n\n\nMany drugs targeting aurora kinases have entered clinical development for solid tumours, most of which have been discontinued in early stages due to modest activity, toxicity or to focus in haematological malignancies (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "163\n, \n164\n, \n165\n, \n166\n In the cell cycle, PLK1 promotes mitotic entry by upregulating CDK1 and inhibiting WEE1 and PKMYT1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "177\n In the presence of chromatid missegregation, the APC is inhibited by the SAC (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "187\n, \n188\n, \n189\n\n\nClinical data is available from BAY1161909, BAY1217389, CFI‐402257 and S81694, with a particular focus on their combination with paclitaxel (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We envision four areas of strategic interest (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "At least four cell cycle checkpoints may be deregulated in breast cancer (BC) cells: the restriction point (G0/G1), the G1 checkpoint (G1/S), the G2 checkpoint (G2/M) and the mitosis‐associated spindle assembly checkpoint (SAC) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "From a mechanistic standpoint, genomic alterations associated with resistance may be divided into two categories: resistance through the disruption of the cell cycle machinery (including alterations in RB1, CCNE1, CDK6, CDK4, p16, CDK2, CDK7, CCND1 or INK) and resistance through compensatory upstream signalling (alterations in PI3K, PTEN, FGFR1/2, FAT1/HIPPO, ERBB2 or RAS signalling) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "59\n A number of pan‐CDK inhibitors (CDKi) have been studied over the last two decades with generally limited anti‐tumour activity and considerable toxicity (Figure 2 and Table 1).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "67\n, \n68\n, \n69\n\n\nFIGURE 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "70\n, \n71\n, \n72\n While the cyclin E‐CDK2 complex participates in the G1/S phase transition through RB1 phosphorylation, CDK7 exerts a wider role in cell cycle progress by acting as a CDK‐activating kinase (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "S PHASE\nEntry into S phase is essentially controlled by the CDK2/cyclinA complex, where CDK2 is activated by CDK4/6‐dependent E2F upregulation and by CDK7, and inhibited by DNA damage‐mediated cdc25A and WEE1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In humans, centriole initiation requires PLK4 serine/threonine kinase activity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "98\n, \n102\n, \n103\n\n,\n\n104\n\n\nSeveral small‐molecule PLK4 inhibitors have been developed with varying selectivity (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "DDR‐related kinases such as ATM and CHK2, and ATR and CHK1, prevent the G2/M transition by activating serine‐threonine kinases WEE1 and PKMYT1, which maintain inhibitory phosphorylation of CDK1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "71\n, \n118\n, \n127\n\n\nFour WEE1i, adavosertib, Debio 0123, IMP7068 and ZN‐c3, have entered clinical trials (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "155\n\n\nMany drugs targeting aurora kinases have entered clinical development for solid tumours, most of which have been discontinued in early stages due to modest activity, toxicity or to focus in haematological malignancies (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "163\n, \n164\n, \n165\n, \n166\n In the cell cycle, PLK1 promotes mitotic entry by upregulating CDK1 and inhibiting WEE1 and PKMYT1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "177\n In the presence of chromatid missegregation, the APC is inhibited by the SAC (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "187\n, \n188\n, \n189\n\n\nClinical data is available from BAY1161909, BAY1217389, CFI‐402257 and S81694, with a particular focus on their combination with paclitaxel (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We envision four areas of strategic interest (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "At least four cell cycle checkpoints may be deregulated in breast cancer (BC) cells: the restriction point (G0/G1), the G1 checkpoint (G1/S), the G2 checkpoint (G2/M) and the mitosis‐associated spindle assembly checkpoint (SAC) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "From a mechanistic standpoint, genomic alterations associated with resistance may be divided into two categories: resistance through the disruption of the cell cycle machinery (including alterations in RB1, CCNE1, CDK6, CDK4, p16, CDK2, CDK7, CCND1 or INK) and resistance through compensatory upstream signalling (alterations in PI3K, PTEN, FGFR1/2, FAT1/HIPPO, ERBB2 or RAS signalling) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "59\n A number of pan‐CDK inhibitors (CDKi) have been studied over the last two decades with generally limited anti‐tumour activity and considerable toxicity (Figure 2 and Table 1).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "67\n, \n68\n, \n69\n\n\nFIGURE 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "70\n, \n71\n, \n72\n While the cyclin E‐CDK2 complex participates in the G1/S phase transition through RB1 phosphorylation, CDK7 exerts a wider role in cell cycle progress by acting as a CDK‐activating kinase (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "S PHASE\nEntry into S phase is essentially controlled by the CDK2/cyclinA complex, where CDK2 is activated by CDK4/6‐dependent E2F upregulation and by CDK7, and inhibited by DNA damage‐mediated cdc25A and WEE1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In humans, centriole initiation requires PLK4 serine/threonine kinase activity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "98\n, \n102\n, \n103\n\n,\n\n104\n\n\nSeveral small‐molecule PLK4 inhibitors have been developed with varying selectivity (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "DDR‐related kinases such as ATM and CHK2, and ATR and CHK1, prevent the G2/M transition by activating serine‐threonine kinases WEE1 and PKMYT1, which maintain inhibitory phosphorylation of CDK1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "71\n, \n118\n, \n127\n\n\nFour WEE1i, adavosertib, Debio 0123, IMP7068 and ZN‐c3, have entered clinical trials (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "155\n\n\nMany drugs targeting aurora kinases have entered clinical development for solid tumours, most of which have been discontinued in early stages due to modest activity, toxicity or to focus in haematological malignancies (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "163\n, \n164\n, \n165\n, \n166\n In the cell cycle, PLK1 promotes mitotic entry by upregulating CDK1 and inhibiting WEE1 and PKMYT1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "177\n In the presence of chromatid missegregation, the APC is inhibited by the SAC (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "187\n, \n188\n, \n189\n\n\nClinical data is available from BAY1161909, BAY1217389, CFI‐402257 and S81694, with a particular focus on their combination with paclitaxel (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We envision four areas of strategic interest (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "At least four cell cycle checkpoints may be deregulated in breast cancer (BC) cells: the restriction point (G0/G1), the G1 checkpoint (G1/S), the G2 checkpoint (G2/M) and the mitosis‐associated spindle assembly checkpoint (SAC) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "From a mechanistic standpoint, genomic alterations associated with resistance may be divided into two categories: resistance through the disruption of the cell cycle machinery (including alterations in RB1, CCNE1, CDK6, CDK4, p16, CDK2, CDK7, CCND1 or INK) and resistance through compensatory upstream signalling (alterations in PI3K, PTEN, FGFR1/2, FAT1/HIPPO, ERBB2 or RAS signalling) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "59\n A number of pan‐CDK inhibitors (CDKi) have been studied over the last two decades with generally limited anti‐tumour activity and considerable toxicity (Figure 2 and Table 1).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "67\n, \n68\n, \n69\n\n\nFIGURE 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "70\n, \n71\n, \n72\n While the cyclin E‐CDK2 complex participates in the G1/S phase transition through RB1 phosphorylation, CDK7 exerts a wider role in cell cycle progress by acting as a CDK‐activating kinase (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "S PHASE\nEntry into S phase is essentially controlled by the CDK2/cyclinA complex, where CDK2 is activated by CDK4/6‐dependent E2F upregulation and by CDK7, and inhibited by DNA damage‐mediated cdc25A and WEE1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In humans, centriole initiation requires PLK4 serine/threonine kinase activity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "98\n, \n102\n, \n103\n\n,\n\n104\n\n\nSeveral small‐molecule PLK4 inhibitors have been developed with varying selectivity (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "DDR‐related kinases such as ATM and CHK2, and ATR and CHK1, prevent the G2/M transition by activating serine‐threonine kinases WEE1 and PKMYT1, which maintain inhibitory phosphorylation of CDK1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "71\n, \n118\n, \n127\n\n\nFour WEE1i, adavosertib, Debio 0123, IMP7068 and ZN‐c3, have entered clinical trials (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "155\n\n\nMany drugs targeting aurora kinases have entered clinical development for solid tumours, most of which have been discontinued in early stages due to modest activity, toxicity or to focus in haematological malignancies (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "163\n, \n164\n, \n165\n, \n166\n In the cell cycle, PLK1 promotes mitotic entry by upregulating CDK1 and inhibiting WEE1 and PKMYT1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "177\n In the presence of chromatid missegregation, the APC is inhibited by the SAC (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "187\n, \n188\n, \n189\n\n\nClinical data is available from BAY1161909, BAY1217389, CFI‐402257 and S81694, with a particular focus on their combination with paclitaxel (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We envision four areas of strategic interest (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "At least four cell cycle checkpoints may be deregulated in breast cancer (BC) cells: the restriction point (G0/G1), the G1 checkpoint (G1/S), the G2 checkpoint (G2/M) and the mitosis‐associated spindle assembly checkpoint (SAC) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "From a mechanistic standpoint, genomic alterations associated with resistance may be divided into two categories: resistance through the disruption of the cell cycle machinery (including alterations in RB1, CCNE1, CDK6, CDK4, p16, CDK2, CDK7, CCND1 or INK) and resistance through compensatory upstream signalling (alterations in PI3K, PTEN, FGFR1/2, FAT1/HIPPO, ERBB2 or RAS signalling) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "59\n A number of pan‐CDK inhibitors (CDKi) have been studied over the last two decades with generally limited anti‐tumour activity and considerable toxicity (Figure 2 and Table 1).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "67\n, \n68\n, \n69\n\n\nFIGURE 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "70\n, \n71\n, \n72\n While the cyclin E‐CDK2 complex participates in the G1/S phase transition through RB1 phosphorylation, CDK7 exerts a wider role in cell cycle progress by acting as a CDK‐activating kinase (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "S PHASE\nEntry into S phase is essentially controlled by the CDK2/cyclinA complex, where CDK2 is activated by CDK4/6‐dependent E2F upregulation and by CDK7, and inhibited by DNA damage‐mediated cdc25A and WEE1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In humans, centriole initiation requires PLK4 serine/threonine kinase activity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "98\n, \n102\n, \n103\n\n,\n\n104\n\n\nSeveral small‐molecule PLK4 inhibitors have been developed with varying selectivity (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "DDR‐related kinases such as ATM and CHK2, and ATR and CHK1, prevent the G2/M transition by activating serine‐threonine kinases WEE1 and PKMYT1, which maintain inhibitory phosphorylation of CDK1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "71\n, \n118\n, \n127\n\n\nFour WEE1i, adavosertib, Debio 0123, IMP7068 and ZN‐c3, have entered clinical trials (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "155\n\n\nMany drugs targeting aurora kinases have entered clinical development for solid tumours, most of which have been discontinued in early stages due to modest activity, toxicity or to focus in haematological malignancies (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "163\n, \n164\n, \n165\n, \n166\n In the cell cycle, PLK1 promotes mitotic entry by upregulating CDK1 and inhibiting WEE1 and PKMYT1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "177\n In the presence of chromatid missegregation, the APC is inhibited by the SAC (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "187\n, \n188\n, \n189\n\n\nClinical data is available from BAY1161909, BAY1217389, CFI‐402257 and S81694, with a particular focus on their combination with paclitaxel (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We envision four areas of strategic interest (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "At least four cell cycle checkpoints may be deregulated in breast cancer (BC) cells: the restriction point (G0/G1), the G1 checkpoint (G1/S), the G2 checkpoint (G2/M) and the mitosis‐associated spindle assembly checkpoint (SAC) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "From a mechanistic standpoint, genomic alterations associated with resistance may be divided into two categories: resistance through the disruption of the cell cycle machinery (including alterations in RB1, CCNE1, CDK6, CDK4, p16, CDK2, CDK7, CCND1 or INK) and resistance through compensatory upstream signalling (alterations in PI3K, PTEN, FGFR1/2, FAT1/HIPPO, ERBB2 or RAS signalling) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "59\n A number of pan‐CDK inhibitors (CDKi) have been studied over the last two decades with generally limited anti‐tumour activity and considerable toxicity (Figure 2 and Table 1).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "67\n, \n68\n, \n69\n\n\nFIGURE 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "70\n, \n71\n, \n72\n While the cyclin E‐CDK2 complex participates in the G1/S phase transition through RB1 phosphorylation, CDK7 exerts a wider role in cell cycle progress by acting as a CDK‐activating kinase (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "S PHASE\nEntry into S phase is essentially controlled by the CDK2/cyclinA complex, where CDK2 is activated by CDK4/6‐dependent E2F upregulation and by CDK7, and inhibited by DNA damage‐mediated cdc25A and WEE1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In humans, centriole initiation requires PLK4 serine/threonine kinase activity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "98\n, \n102\n, \n103\n\n,\n\n104\n\n\nSeveral small‐molecule PLK4 inhibitors have been developed with varying selectivity (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "DDR‐related kinases such as ATM and CHK2, and ATR and CHK1, prevent the G2/M transition by activating serine‐threonine kinases WEE1 and PKMYT1, which maintain inhibitory phosphorylation of CDK1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "71\n, \n118\n, \n127\n\n\nFour WEE1i, adavosertib, Debio 0123, IMP7068 and ZN‐c3, have entered clinical trials (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "155\n\n\nMany drugs targeting aurora kinases have entered clinical development for solid tumours, most of which have been discontinued in early stages due to modest activity, toxicity or to focus in haematological malignancies (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "163\n, \n164\n, \n165\n, \n166\n In the cell cycle, PLK1 promotes mitotic entry by upregulating CDK1 and inhibiting WEE1 and PKMYT1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "177\n In the presence of chromatid missegregation, the APC is inhibited by the SAC (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "187\n, \n188\n, \n189\n\n\nClinical data is available from BAY1161909, BAY1217389, CFI‐402257 and S81694, with a particular focus on their combination with paclitaxel (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We envision four areas of strategic interest (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "At least four cell cycle checkpoints may be deregulated in breast cancer (BC) cells: the restriction point (G0/G1), the G1 checkpoint (G1/S), the G2 checkpoint (G2/M) and the mitosis‐associated spindle assembly checkpoint (SAC) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "From a mechanistic standpoint, genomic alterations associated with resistance may be divided into two categories: resistance through the disruption of the cell cycle machinery (including alterations in RB1, CCNE1, CDK6, CDK4, p16, CDK2, CDK7, CCND1 or INK) and resistance through compensatory upstream signalling (alterations in PI3K, PTEN, FGFR1/2, FAT1/HIPPO, ERBB2 or RAS signalling) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "59\n A number of pan‐CDK inhibitors (CDKi) have been studied over the last two decades with generally limited anti‐tumour activity and considerable toxicity (Figure 2 and Table 1).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "67\n, \n68\n, \n69\n\n\nFIGURE 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "70\n, \n71\n, \n72\n While the cyclin E‐CDK2 complex participates in the G1/S phase transition through RB1 phosphorylation, CDK7 exerts a wider role in cell cycle progress by acting as a CDK‐activating kinase (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "S PHASE\nEntry into S phase is essentially controlled by the CDK2/cyclinA complex, where CDK2 is activated by CDK4/6‐dependent E2F upregulation and by CDK7, and inhibited by DNA damage‐mediated cdc25A and WEE1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In humans, centriole initiation requires PLK4 serine/threonine kinase activity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "98\n, \n102\n, \n103\n\n,\n\n104\n\n\nSeveral small‐molecule PLK4 inhibitors have been developed with varying selectivity (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "DDR‐related kinases such as ATM and CHK2, and ATR and CHK1, prevent the G2/M transition by activating serine‐threonine kinases WEE1 and PKMYT1, which maintain inhibitory phosphorylation of CDK1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "71\n, \n118\n, \n127\n\n\nFour WEE1i, adavosertib, Debio 0123, IMP7068 and ZN‐c3, have entered clinical trials (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "155\n\n\nMany drugs targeting aurora kinases have entered clinical development for solid tumours, most of which have been discontinued in early stages due to modest activity, toxicity or to focus in haematological malignancies (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "163\n, \n164\n, \n165\n, \n166\n In the cell cycle, PLK1 promotes mitotic entry by upregulating CDK1 and inhibiting WEE1 and PKMYT1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "177\n In the presence of chromatid missegregation, the APC is inhibited by the SAC (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "187\n, \n188\n, \n189\n\n\nClinical data is available from BAY1161909, BAY1217389, CFI‐402257 and S81694, with a particular focus on their combination with paclitaxel (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We envision four areas of strategic interest (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "At least four cell cycle checkpoints may be deregulated in breast cancer (BC) cells: the restriction point (G0/G1), the G1 checkpoint (G1/S), the G2 checkpoint (G2/M) and the mitosis‐associated spindle assembly checkpoint (SAC) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "From a mechanistic standpoint, genomic alterations associated with resistance may be divided into two categories: resistance through the disruption of the cell cycle machinery (including alterations in RB1, CCNE1, CDK6, CDK4, p16, CDK2, CDK7, CCND1 or INK) and resistance through compensatory upstream signalling (alterations in PI3K, PTEN, FGFR1/2, FAT1/HIPPO, ERBB2 or RAS signalling) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "59\n A number of pan‐CDK inhibitors (CDKi) have been studied over the last two decades with generally limited anti‐tumour activity and considerable toxicity (Figure 2 and Table 1).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "67\n, \n68\n, \n69\n\n\nFIGURE 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "70\n, \n71\n, \n72\n While the cyclin E‐CDK2 complex participates in the G1/S phase transition through RB1 phosphorylation, CDK7 exerts a wider role in cell cycle progress by acting as a CDK‐activating kinase (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "S PHASE\nEntry into S phase is essentially controlled by the CDK2/cyclinA complex, where CDK2 is activated by CDK4/6‐dependent E2F upregulation and by CDK7, and inhibited by DNA damage‐mediated cdc25A and WEE1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In humans, centriole initiation requires PLK4 serine/threonine kinase activity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "98\n, \n102\n, \n103\n\n,\n\n104\n\n\nSeveral small‐molecule PLK4 inhibitors have been developed with varying selectivity (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "DDR‐related kinases such as ATM and CHK2, and ATR and CHK1, prevent the G2/M transition by activating serine‐threonine kinases WEE1 and PKMYT1, which maintain inhibitory phosphorylation of CDK1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "71\n, \n118\n, \n127\n\n\nFour WEE1i, adavosertib, Debio 0123, IMP7068 and ZN‐c3, have entered clinical trials (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "155\n\n\nMany drugs targeting aurora kinases have entered clinical development for solid tumours, most of which have been discontinued in early stages due to modest activity, toxicity or to focus in haematological malignancies (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "163\n, \n164\n, \n165\n, \n166\n In the cell cycle, PLK1 promotes mitotic entry by upregulating CDK1 and inhibiting WEE1 and PKMYT1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "177\n In the presence of chromatid missegregation, the APC is inhibited by the SAC (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "187\n, \n188\n, \n189\n\n\nClinical data is available from BAY1161909, BAY1217389, CFI‐402257 and S81694, with a particular focus on their combination with paclitaxel (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We envision four areas of strategic interest (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "At least four cell cycle checkpoints may be deregulated in breast cancer (BC) cells: the restriction point (G0/G1), the G1 checkpoint (G1/S), the G2 checkpoint (G2/M) and the mitosis‐associated spindle assembly checkpoint (SAC) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "At least four cell cycle checkpoints may be deregulated in breast cancer (BC) cells: the restriction point (G0/G1), the G1 checkpoint (G1/S), the G2 checkpoint (G2/M) and the mitosis‐associated spindle assembly checkpoint (SAC) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "From a mechanistic standpoint, genomic alterations associated with resistance may be divided into two categories: resistance through the disruption of the cell cycle machinery (including alterations in RB1, CCNE1, CDK6, CDK4, p16, CDK2, CDK7, CCND1 or INK) and resistance through compensatory upstream signalling (alterations in PI3K, PTEN, FGFR1/2, FAT1/HIPPO, ERBB2 or RAS signalling) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "59\n A number of pan‐CDK inhibitors (CDKi) have been studied over the last two decades with generally limited anti‐tumour activity and considerable toxicity (Figure 2 and Table 1).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "67\n, \n68\n, \n69\n\n\nFIGURE 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "70\n, \n71\n, \n72\n While the cyclin E‐CDK2 complex participates in the G1/S phase transition through RB1 phosphorylation, CDK7 exerts a wider role in cell cycle progress by acting as a CDK‐activating kinase (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "From a mechanistic standpoint, genomic alterations associated with resistance may be divided into two categories: resistance through the disruption of the cell cycle machinery (including alterations in RB1, CCNE1, CDK6, CDK4, p16, CDK2, CDK7, CCND1 or INK) and resistance through compensatory upstream signalling (alterations in PI3K, PTEN, FGFR1/2, FAT1/HIPPO, ERBB2 or RAS signalling) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "From a mechanistic standpoint, genomic alterations associated with resistance may be divided into two categories: resistance through the disruption of the cell cycle machinery (including alterations in RB1, CCNE1, CDK6, CDK4, p16, CDK2, CDK7, CCND1 or INK) and resistance through compensatory upstream signalling (alterations in PI3K, PTEN, FGFR1/2, FAT1/HIPPO, ERBB2 or RAS signalling) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "59\n A number of pan‐CDK inhibitors (CDKi) have been studied over the last two decades with generally limited anti‐tumour activity and considerable toxicity (Figure 2 and Table 1).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "67\n, \n68\n, \n69\n\n\nFIGURE 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "70\n, \n71\n, \n72\n While the cyclin E‐CDK2 complex participates in the G1/S phase transition through RB1 phosphorylation, CDK7 exerts a wider role in cell cycle progress by acting as a CDK‐activating kinase (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "59\n A number of pan‐CDK inhibitors (CDKi) have been studied over the last two decades with generally limited anti‐tumour activity and considerable toxicity (Figure 2 and Table 1).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "70\n, \n71\n, \n72\n While the cyclin E‐CDK2 complex participates in the G1/S phase transition through RB1 phosphorylation, CDK7 exerts a wider role in cell cycle progress by acting as a CDK‐activating kinase (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "S PHASE\nEntry into S phase is essentially controlled by the CDK2/cyclinA complex, where CDK2 is activated by CDK4/6‐dependent E2F upregulation and by CDK7, and inhibited by DNA damage‐mediated cdc25A and WEE1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In humans, centriole initiation requires PLK4 serine/threonine kinase activity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "98\n, \n102\n, \n103\n\n,\n\n104\n\n\nSeveral small‐molecule PLK4 inhibitors have been developed with varying selectivity (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Entry into S phase is essentially controlled by the CDK2/cyclinA complex, where CDK2 is activated by CDK4/6‐dependent E2F upregulation and by CDK7, and inhibited by DNA damage‐mediated cdc25A and WEE1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "In humans, centriole initiation requires PLK4 serine/threonine kinase activity (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Several small‐molecule PLK4 inhibitors have been developed with varying selectivity (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "DDR‐related kinases such as ATM and CHK2, and ATR and CHK1, prevent the G2/M transition by activating serine‐threonine kinases WEE1 and PKMYT1, which maintain inhibitory phosphorylation of CDK1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "71\n, \n118\n, \n127\n\n\nFour WEE1i, adavosertib, Debio 0123, IMP7068 and ZN‐c3, have entered clinical trials (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "155\n\n\nMany drugs targeting aurora kinases have entered clinical development for solid tumours, most of which have been discontinued in early stages due to modest activity, toxicity or to focus in haematological malignancies (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "163\n, \n164\n, \n165\n, \n166\n In the cell cycle, PLK1 promotes mitotic entry by upregulating CDK1 and inhibiting WEE1 and PKMYT1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "DDR‐related kinases such as ATM and CHK2, and ATR and CHK1, prevent the G2/M transition by activating serine‐threonine kinases WEE1 and PKMYT1, which maintain inhibitory phosphorylation of CDK1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "71\n, \n118\n, \n127\n\n\nFour WEE1i, adavosertib, Debio 0123, IMP7068 and ZN‐c3, have entered clinical trials (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Four WEE1i, adavosertib, Debio 0123, IMP7068 and ZN‐c3, have entered clinical trials (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "155\n\n\nMany drugs targeting aurora kinases have entered clinical development for solid tumours, most of which have been discontinued in early stages due to modest activity, toxicity or to focus in haematological malignancies (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Many drugs targeting aurora kinases have entered clinical development for solid tumours, most of which have been discontinued in early stages due to modest activity, toxicity or to focus in haematological malignancies (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "163\n, \n164\n, \n165\n, \n166\n In the cell cycle, PLK1 promotes mitotic entry by upregulating CDK1 and inhibiting WEE1 and PKMYT1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "163\n, \n164\n, \n165\n, \n166\n In the cell cycle, PLK1 promotes mitotic entry by upregulating CDK1 and inhibiting WEE1 and PKMYT1 (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "177\n In the presence of chromatid missegregation, the APC is inhibited by the SAC (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "187\n, \n188\n, \n189\n\n\nClinical data is available from BAY1161909, BAY1217389, CFI‐402257 and S81694, with a particular focus on their combination with paclitaxel (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "177\n In the presence of chromatid missegregation, the APC is inhibited by the SAC (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "187\n, \n188\n, \n189\n\n\nClinical data is available from BAY1161909, BAY1217389, CFI‐402257 and S81694, with a particular focus on their combination with paclitaxel (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "177\n In the presence of chromatid missegregation, the APC is inhibited by the SAC (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Clinical data is available from BAY1161909, BAY1217389, CFI‐402257 and S81694, with a particular focus on their combination with paclitaxel (Figure 2 and Table 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "We envision four areas of strategic interest (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "We envision four areas of strategic interest (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 2,
    "claims_count": 158,
    "images_downloaded": 2,
    "tables_filtered": 301
  }
}